Quercetin (Qc) has high antioxidant activity which reduces the toxicity of those drugs due to the poor solubility of those drugs [10]. The topical inflammatory disorders such as psoriasis and arthritis [5]. A number of OH groups in their structure so they are used in topical treatment. Optimization of production parameters to produce stable, -time-released, and -targeted drug delivery systems is urgent and is needed for herbal drugs as flavonoids which are also found in fruits and vegetables, have many physiological activities [2]. Nanotechnology is urgently needed for herbal drugs like Quercetin to be used as successful drug delivery systems.

INTRODUCTION

Herbal drugs have been used in many diseases [1]. Plant pigments which are found in herbal drugs as flavonoids which are also found in fruits and vegetables, have many physiological activities [2]. Flavonoids are important drug candidates due to their free radical scavenging and anti-inflammatory properties [3, 4]. There is a structure-activity relationship between several flavonoids (luteolin, kaempferol, and quercetin) and their antioxidant activity and the number of OH groups in their structure so they are used in inflammatory disorders such as psoriasis and arthritis [5].

Quercetin (Qc) has high antioxidant activity which reduces the expression of matrix metalloproteinase that causes wrinkling and decreasing of the elasticity of healthy and photosaged skin [6]. Qc has antioxidant and anti-radical effects due to three functional groups in its structure [7-9]. Nanotechnology is urgently needed for herbal drugs due to the poor solubility of those drugs [10]. The topical application of Qc in various formulation approaches includes permeation enhancers [11] such as lecithin and chitosan nanoparticles which increase the penetration of Qc through the skin to make its topical and transdermal delivery easier, targeting the drug towards the desired tissue and concentrating the drug in it while reducing its concentration in the non-target tissues. Hence, drug action increases and side effects decrease [13]. Topical dosage forms are superior drug delivery systems because they avoid first-pass hepatic metabolism, gastric degradation and improve penetration of the drug into skin layers [14, 15]. Surface-active agent vesicles are an alternative drug delivery system to conventional liposomes. Transfersomes (TFs) are elastic nano-vesicles composed of lecithin and surface-active agent and they differ from the conventional liposomes by their ability to squeeze themselves into the intercellular region of the stratum corneum [16, 17].

This study aimed to develop topical Qc-loaded TFs for wound treatment. Optimization of production parameters to produce stable, highly concentrated Qc vesicles with a small particle size was done using full factorial statistical design. In addition, in vivo skin deposition of Qc from optimum TFs was compared with Qc liposomes and Qc suspension using male Wistar rats. In addition, wound induction was done to male Wistar rats which were then treated with Qc optimum TFs, Qc liposomes, and Qc suspension by measuring the biological parameters in the treated skin tissues of rats. Furthermore, two in vivo histopathological experiments were performed; the first to compare the wound treatment effect of Qc optimum TFs, Qc liposomes, and Qc suspension. The second in vivo histopathological experiment was performed to assess the irritation potential of Qc optimum TFs on rat skin.

MATERIALS AND METHODS

Materials

Quercetin (Qc) dihydrate 97%, Cholesterol 95%, and Polysorbate 60 (Tweens 60) were purchased from ALFA Aesar (A Johnson Matthey Company), Germany. Ethanol absolute was purchased from Sigma Aldrich, Germany. Cholestrorm was purchased from Sigma Aldrich, United Kingdom. Sodium Chloride, Potassium chloride, Disodium hydrogen orthophosphate, Potassium dihydrogen orthophosphate, and Tween 60 were purchased from ADWIC, Elnasar pharmaceutical chemicals company, Egypt. Span 60 and Span 40 were purchased from LOBA Chemie, India. Lecithin granular from egg yolk was purchased from Acros organics, USA. Sorbitan monoleate (Span80) was purchased from MP Biomedicals, France. Glutathione reduced (GSH), Malonaldehyde (MDA), Nitric oxide (NO), Total proteins (TP) and Total antioxidant capacity (TAC) kits colorimetric method were purchased from Biodynamic and research reagents, Egypt.

Experimental design

The design was used was complete factorial 241 which studied the influence of different variables on Qc-loaded TFs [18]. One factor was assessed with 4 levels (X1: Type of the surface-active agent), while the others with two levels (X2: Lecithin to surface-active agent molar ratio) and (X3: Hydration volume). Y1: EE %), Y2: PS), (Y3: PDI), (Y4: ZP).
Preparation by thin-film hydration technique

Preparation of TFs was performed by thin-film hydration technique [19] as follows: specified weights of Qc, lecithin from egg yolk, Span 60, Tween 80, were dissolved in 20 ml (chloroform and ethanol, 1:1 v/v) then were put in a rotary-evaporator (Rotavapor, Heidolph VV 2000, Burladingen, Germany). The solvent was evaporated at 60 °C, then the thin layer formed was rehydrated by saline phosphate buffer at 60 °C with agitation using glass beads followed by sonication. To compare the permeation of the prepared TFs and other vesicles; Qc liposomes (composed of Qc and lecithin from egg yolk) were prepared in the same method and amounts as above.

Qc loaded TFs characterization

Measurement of PS, PDI, and ZP

Measurement of PS (z-average), PDI, and ZP of the prepared TFs suspensions was performed by Photon Correlation Spectroscopy (PCS) using a Zetasizer Nano ZS-90 instrument (Malvern Instruments, Worcestershire, UK). TFs suspensions were diluted before the measurement. Measurements were performed in triplicate using a 90 °C scattering angle at 25 °C. PS, PDI, and ZP of the prepared TFs suspensions was performed by Photon Correlation Spectroscopy (PCS).

Determination of Qc EE% in TFs

The difference between the total amount of Qc added in the formulation and that remaining in the aqueous medium, after separating the TFs suspension by centrifugation at 8500 rpm for 30 min using a centrifuge (Biofuge primo Heraeus instruments, Germany), was calculated to determine the EE% of Qc TFs. EE% was calculated using the equation:

\[
EE(\%) = \left( \frac{\text{Total amount of Qc added} - \text{amount of free Qc}}{\text{Total amount of Qc added}} \right) \times 100
\]

Formulation optimization

The optimum formula was obtained using the Design Expert® software by applying constraints on encapsulation efficiency percent of the TFs to reach the maximum value, ZP to obtain the maximum as an absolute value and on particle size and PDI to obtain the smallest value.

TEM

The particle shape of the Qc optimum TFs suspension was visualized using JEM-2100 Electron Microscope, Japan. A drop of TFs suspension was placed onto a film-coated copper grid, to make a thin film, before the specimen was dried on the grid. A drop of 1% phosphotungstic acid was used to stain the above film. The grid was then viewed at an accelerating voltage of 200KV [22].

Assay of Qc by HPLC

A gradient HPLC method was chosen for the assay of Qc [25]. Waters 2690 Alliance HPLC system detector (America) was used, and the detector used was a UV detector. The type of column was C18 thermo column (4.6 mm x 250 mm). The temperature of the column was maintained at room temperature (25.0±2.0 °C). Mobile phase A was 0.1% Phosphoric acid and mobile phase B was acetonitrile. The flow rate was 0.5 ml/min and the UV detector was set at 262 nm. Data analyses were made using SAS, (1999). Comparison of means was done using Duncan’s at 5% level of significance [26].

Cutaneous wound induction and treatment

Forty-eight male Wistar rats were used in the experiment. Anesthesia was made by intraperitoneal injection of ketamine and xylazine, and then shaving to the thoracodorsal part was done. A square-shaped
wound 400 mm² thick was created on the back of the rats using a scalpel blade and forceps [27]. After recovery from anesthesia animals were grouped in cages into 4 groups with twelve rats in each group. Treatment was done daily as follows: Group (I), Group (II), Group (III), and Group (IV) were treated with specified amounts of buffer (control), Qc suspension, Qc liposomes, and Qc optimum TFs, respectively. At the end of the experiment after 15 d, the rats of each group were killed and the healing tissue was collected and divided into two portions. The first portion was stored at -20°C and then homogenized in phosphate buffer saline (pH=7.4). The tissue homogenates were centrifuged for 20 min at 12000 rpm and 4 °C and the following biological parameters were estimated in the supernatants: GSH [28], MDA [29, 30], NO [31], TP [32], and TAC assay [33]. The second portion was used for the histopathological examination according to the above protocol [34].

RESULTS AND DISCUSSION

Characterization of Qc loaded TFs

Formulation variables effect on EE%

Entrapment of TFs of a significant amount of Qc is important for its use for topical application. Entrapment of Qc in TFs ranged from 85.80 to 98.38%. Results of the entrapment efficiency in the TFs formulae are presented in table 2. 3-D plots in fig. 1 illustrate the effect of type of surface-active agent, lecithin to surface-active agent molar ratio, and hydration volume on EE%. ANOVA results showed that only type of surface-active agent and hydration volume had a significant effect on EE% (P<0.0001).

This could be explained by the hydrophobicity of Qc. Hence, surface-active agent with low HLB values showed higher EE% than surface-active agent with high HLB values. TFs containing Span 60 and Span 80 with HLB 4.7 and HLB 4.3, respectively, displayed EE% higher than formulae containing Tween 60 and Tween 80 with HLB 14.9 and HLB 15, respectively. In addition, increasing hydration volume decreased the EE%. When the hydration volume increases, the drug entrapment in the lipid bilayers decreases, and its partition in the aqueous phase increases [35].

Formulation variables effect on PS

Small particles pass through skin more than larger ones [36, 37]. The results of PS of TFs are presented as Z average diameter in table 2 [39]. The PS of TFs composed of Tween 60 in size between 674.2 and 1323.6 nm. The influence of the type of surface-active agent, lecithin to surface-active agent molar ratio, and hydration volume is presented as 3D plots in fig. 1. Factorial analysis showed that only the type of surface-active agent had a significant effect on PS (P<0.0001).

Formulation variables effect on ZP

Wholly monodispersed particles have PDI of 0, while highly polydispersed particles have PDI of 1 [40]. All TFs ranged from 0.335 to 1. The influence of the type of surface-active agent, lecithin to surface-active agent molar ratio, and hydration volume is presented as 3-D surface plots in fig. 2. Factorial analysis showed that two factors had a significant effect on PDI (P<0.01).

Formulation variables effect on ZP

ZP is the measure of the total charges acquired by vesicles. Any formula is considered stable when the zeta potential value is around±30 mV because of electrical repulsion between particles [41].

The obtained ZP values of TFs formulae ranged from -6.63 to -19.9 to mV. The values of ZP of TFs formulae are presented in table 2. Because ZP was negative in all the formulations in our study, the discussion of variation in ZP will be in terms of its absolute value. The influence of the type of surface-active agent, lecithin to surface-active agent molar ratio, and hydration volume is presented as 3-D surface plots in fig. 2. Factorial analysis showed that the type of surface-active agent and lecithin to surface-active agent molar ratio had a significant effect on zeta potential (P<0.0001 and P<0.01, respectively).

Decreasing lipophilicity of surface-active agents increased ZP due to the reduction of the surface free energy of the surface-active agent. Accordingly, formulae from 9 to 16 containing Span 60 and Span 80 showed particle size higher than formulae from 1 to 8 containing Tween 60 and Tween 80. This could be attributed to that Tweens have more

### Table 2: Formulations, independent variables, and measured responses of the 2⁴ full factorial experimental design of TFs formulae

| Formulations | X₁ | X₂ | X₃ | X₄ | EE% | PS (nm) | PDI | ZP (mV) |
|--------------|----|----|----|----|-----|--------|-----|--------|
| F1           | Tween60 | 5:1 | 10 | 90.40±0.56 | 90.0±0.50 | 0.65±0.16 | -8.3±1.47 |
| F2           | Tween60 | 5:1 | 20 | 90.21±0.57 | 1170.50±272.73 | 1.33±0.22 | -9.4±0.26 |
| F3           | Tween60 | 5:1 | 20 | 88.70±0.98 | 1323.60±679.30 | 0.90±0.13 | -6.8±0.74 |
| F4           | Tween60 | 5:1 | 20 | 87.85±0.91 | 795.85±51.68 | 0.47±0.03 | -8.8±0.82 |
| F5           | Tween80 | 5:1 | 20 | 90.11±0.72 | 90.0±0.50 | 3.54±0.60 | -9.1±0.28 |
| F6           | Tween80 | 5:1 | 20 | 91.10±0.14 | 695.35±20.29 | 0.59±0.03 | -11.10±0.14 |
| F7           | Tween80 | 5:1 | 20 | 85.80±0.12 | 1029.50±13.40 | 0.72±0.24 | -8.2±0.40 |
| F8           | Tween80 | 5:1 | 20 | 86.60±0.56 | 674.20±1.27 | 0.51±0.00 | -10.45±1.23 |
| F9           | Span60  | 5:1 | 10 | 98.38±0.02 | 3088.50±39.70 | 0.67±0.45 | -15.45±1.76 |
| F10          | Span60  | 5:1 | 10 | 97.70±0.11 | 2796.50±91.21 | 1.00±0.37 | -15.70±0.70 |
| F11          | Span60  | 5:1 | 20 | 94.85±0.07 | 2951.00±255.90 | 0.73±0.00 | -18.45±1.34 |
| F12          | Span60  | 5:1 | 20 | 97.45±0.52 | 2912.50±436.28 | 1.00±0.31 | -18.15±1.48 |
| F13          | Span80  | 5:1 | 10 | 93.80±1.13 | 2576.30±19.09 | 0.77±0.47 | -18.61±1.83 |
| F14          | Span80  | 5:1 | 10 | 92.10±0.26 | 3195.00±573.46 | 0.66±0.47 | -18.90±0.98 |
| F15          | Span80  | 5:1 | 20 | 87.80±2.62 | 3105.00±289.90 | 0.72±0.38 | -17.55±0.49 |
| F16          | Span80  | 5:1 | 20 | 90.50±0.70 | 3371.00±254.67 | 0.75±0.34 | -16.95±0.49 |

*Data represented as mean±SD (n = 3). Abbreviations: EE%, entrapment efficiency percent; PS, particle size; PDI, polydispersity index, and ZP, zeta-potential.

Formulation variables effect on PDI

Wholly monodispersed particles have PDI of 0, while highly polydispersed particles have PDI of 1 [40]. All TFs ranged from 0.335 to 1. The influence of the type of surface-active agent, lecithin to surface-active agent molar ratio, and hydration volume is presented as 3-D surface plots in fig. 2. Factorial analysis showed that two factors had a significant effect on PDI (P<0.01).

Formulation variables effect on ZP

ZP is the measure of the total charges acquired by vesicles. Any formula is considered stable when the zeta potential value is around±30 mV because of electrical repulsion between particles [41].
Span 80 with HLB 4.7 and HLB 4.3, respectively, had higher ZP than formulae from 1 to 8 containing Tween 60 and Tween 80 with HLB 14.9 and HLB 15, respectively [42]. Also, the lecithin to surface-active agent molar ratio had a significant effect on ZP. The isoelectric point of lecithin is between 6-7; therefore, it is a zwitterionic compound since the pH of the saline buffer is 7.4, which is higher than the isoelectric point and since we use a nonionic surface-active agent, therefore, the net charge is negative therefore ZP is negative. The negativity of ZP was also due to the presence of hydroxyl ion on the surface of the vesicles [43]. When lecithin to surface-active agent molar ratio increased, ZP increased because the negative charge increased [44, 45].

Fig. 1: Response 3D-plots of the effect of type of surface-active agent, lecithin to surface-active agent molar ratio, and hydration volume on the EE% and PS of TFs

Fig. 2: Response 3D-plots of the effect of type of surface-active agent, lecithin to surface-active agent molar ratio, and hydration volume on the PDI, and ZP of TFs
Optimum formulation

Using Design Expert® software, the optimum formulation was found to be F6. Choosing the optimum formulation was according to the following criteria (achieving the maximum value of EE%, minimum values of PS and PDI, and maximum value of ZP as absolute value). F6 was prepared with Tween 80, lecithin: surfactant agent molar ratio of 10:1, and hydration volume of 10 ml. This formulation showed EE% of 91.1%, PS of 695.35 nm, PDI of 0.592, and ZP of -11.1 mV.

TEM

TEM analysis was used to verify the results of the Malvern analyzer of PS and also to examine the shape of the vesicular system [46]. Fig. 3 shows the TEM image of F6. The vesicles are non-aggregated, unilamellar, and spherical in shape. The size of the TEM agrees with that obtained from the Malvern particle size analyzer.

DSC

Fig. 4 shows the DSC thermogram of Qc, Tween 80, lecithin egg yolk, physical mixture of Qc with TFs components, and F6. Qc has two endothermic peaks at 122.5 °C and 320 °C [47]. Lecithin egg yolk has four endothermic peaks at 143.78 °C, 182.45 °C, 237.85 °C, and 265.88 °C [48, 49]. Tween 80 shows one endothermic peak at 64.34 °C [50]. In the peaks of the physical mixture of Qc with the TFs constituents, the endothermic peak of Qc appears but less sharp due to its dilution with the excipients [51, 52]. In F6, the endothermic peak of Qc disappears due to inhibition of its re-crystallization and solubilization in TFs and its appearance in the more soluble and amorphous state, which leads to a high energy state which enhanced its solubility [53, 54].

In vivo assessment of Qc loaded TFs

In vivo skin deposition experiment

Fig. 5 shows the in vivo skin deposition profile from Qc suspension, Qc liposomes, and F6. Drug percentage retained in the skin from F6 was significantly higher than Qc liposomes and Qc suspension at 2h, 4h, 6h, 8h, and 10h (p < 0.05) (table 3). The percentage of Qc deposited from F6 in rat skin was 1.89 times higher than that from Qc liposomes and 4.3 times higher than Qc suspension. The higher Qc skin deposition from TFs could be due to the higher elasticity of TFs when compared to conventional liposomes as they have deformable properties, which can make them easily squeeze through the channels of the stratum corneum [55]. TFs are drug carrier systems that can penetrate the skin. The unimpeded moving of such carriers depends on two factors: the vesicle bilayers are very elastic and the presence of an osmotic gradient through the skin. Accordingly, TFs pass through the skin because their membrane is flexible, which prevents the rupture of the vesicles in the skin and permits the ultra-deformability of the TFs to change the composition of their membrane locally and reversibly when they are attracted to narrow pore. This decreases the percentage of membrane deformation and permits the flexible particles first to pass rapidly [56].

Fig. 3: TEM of Qc optimum TFs formulation (F6)

Fig. 4: DSC thermograms of (i) Qc, (ii) lecithin egg yolk, (iii) Tween 80, (iv) physical mixture, and (v) F6
Cutaneous wound induction and treatment

Biochemical parameters

Wound induction undergoes an imbalance between production and accumulation of reactive oxygen species (ROS) in cells and tissues and this phenomenon is called oxidative stress and occurs by neutrophils which are derived from oxidants and MPO due to inflammation of wounds [57]. Biochemical parameters are shown in table 4.

Table 3: Statistical analysis of in vivo deposition study

| % Qc deposited | Time (h) | 1 | 2 | 4 | 6 | 8 | 10 |
|----------------|---------|---|---|---|---|---|----|
| Qc suspension | 78.50±10.00 | 40.60±0.52 | 11.20±0.25 | 9.40±0.72 | 9.40±0.23 | 9.40±0.06 |
| Qc liposomes  | 97±10.00  | 76±0.40    | 13.48±0.30 | 13.48±0.90 | 13.48±0.50 | 13.48±0.03 |
| F6            | 99±10.00  | 86.90±10.00| 84.74±1.10 | 53.57±1.00 | 48.10±0.10 | 45.10±0.10 |

Means in the same column with small letters are significantly different (p<0.05), n=3±SD.

Histopathological examination

Fig. 6 shows the histopathological findings of the second section of the wound induction experiment. H and E stained wound sections were magnified at different levels. Control group (I) demonstrated retarded wound healing process with the persistence of a wide wound gap. Incomplete re-epithelialization due to immature epithelial layer and the presence of ulceration (arrow) with scab formed from necrotic tissue depresses and inflammatory cells infiltration (dashed arrow). Highly cellular granulation tissue with less mature collagen fibers is found in the dermis (star). Group treated with Qc suspension (II) demonstrated the same records as a control group with retarded wound healing process under scab (dashed arrow) with incomplete re-epithelialization and granulation tissue formation in dermal layer (star) accompanied with severe inflamed cells infiltrations and several congested and dilated deeper blood vessels (arrows). Group (III) treated with Qc liposomes showed incomplete healing with the persistence of a wide wound gap surrounded with granulation tissue (arrow) under scab from necrotic tissue depress and severe inflammatory cells infiltrates.
Group (IV) treated with F6 revealed the best wound healing with full re-epithelialization of the epidermis (arrow) and mature collagen made of fibers in the dermis with several hair follicles which were active and small amounts of inflamed cells. Remnant of old granulation tissue could be detected in the sub-epithelial region of the epidermis. Table 5 shows the difference between groups in collagen percentage. Collagen percentage in F6 was significantly higher than control, Qc suspension, and Qc liposomes. Fig. 7 shows histopathological examination for collagen. F6 showed a higher inflammatory response, accelerated.

Table 5: Collagen percentage in different groups after wound treatment

| Area percentage of dermal collagen fibers | Groups         | Control        | Qc suspension | Qc Liposomes | F6            |
|------------------------------------------|---------------|----------------|---------------|--------------|---------------|
|                                          |               | 9.68±0.79      | 10.60±1.20    | 16.50±1.37   | 35.20±1.44    |

Means in the same row with different small letters are significantly different (p < 0.05), (n=6±SD)

Fig. 6: Photomicrographs showing histopathological sections (Harris hematoxylin and eosin-stained) of treated groups after wound induction: the untreated control group (I), the group treated with Qc suspension (II), the group treated with Qc liposomes (III), and the group treated with F6 (IV)

Fig. 7: Photomicrographs showing histopathological sections (Masson’s Trichrome stain for demonstration of collagen fibers) of treated groups after wound induction: the untreated control group (I), the group treated with Qc suspension (II), the group treated with Qc liposomes (III), and the group treated with F6 (IV)

Wound healing and collagen percentage than Qc liposomes and Qc suspension as TFs were able to squeeze into the inside region of the outer layer of the skin (stratum corneum) and exhibit the anti-inflammatory and antioxidant activity because TFs are deformable so that it can go to the pores which are smaller than their size. On the contrary, Qc suspension and Qc liposomes didn’t squeeze in the intercellular layer of the stratum corneum so they showed retardation in wound healing and antioxidant activity [56, 66].

For the second histopathological study, fig. 8 shows microscopic pictures of rat skin sections that were stained: group (I), group (II), group (III), and group (IV) for control, Qc suspension, Qc liposomes, and F6, respectively. Microscopic examination of different skin samples from all groups revealed normal morphological features of different skin layers, including epidermis with intact keratinocytes, (Black arrows) dermis with mature collagen fibers, and many active hair follicles (red star) intact subcutaneous tissue muscles, and tissue (black star). No abnormal tissue alterations could be detected.
Fig. 8: Photomicrographs showing histopathological sections (Harris hematoxylin and eosin-stained) of the control group (I), the group treated with topical application of Qc suspension (II), the group treated with topical application of Qc liposomes suspension (III), and the group treated with topical application of F6 (IV)

CONCLUSION
Qc-loaded TFs were used topically for wound treatment. Statistical optimization of formulation variables was performed by factorial design using Design-Expert® software. The Qc optimum TFs (F6) formulation had a spherical shape, EE% of 91.1%, the particle size of 695.35 nm, PDI of 0.592, and ZP of -11.1 mV. In vivo skin deposition experiment showed that F6 was superior compared to Qc suspension and Qc liposomes. In addition, cutaneous wound treatment displayed that F6 was superior to Qc suspension and Qc liposomes. Furthermore, in vivo histopathological experiment confirmed that the topically applied F6 was not irritant. Therefore, the results proved that Qc-loaded TFs could be used as a successful drug delivery system to be used for wound healing.

FUNDING
Nil

AUTHORS CONTRIBUTIONS
All authors have contributed equally.

CONFLICT OF INTERESTS
Declared none

REFERENCES
1. Theng MA, GR Sitaphale, KR Biyani. Evaluation of wound healing activity of polyherbal formulation. Int J Carr Pharm Res 2017;9:1-4.
2. Awad MA, A de Jager, LM van Westing. Flavonoid and chlorogenic acid levels in apple fruit: characterization of variation. Sci Horticulturae 2000;83:249-63.
3. Pietta PG. Flavonoids as antioxidants. J Nat Prod 2000;63:1035-42.
4. Guardia T. Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat. Farmaco 2001;56:683-7.
5. Vijayalakshmi A, G Madhira. Anti-psoriatic activity of flavonoids from Cassia tora leaves using the rat ultraviolet B ray photodermatitis model. Rev Brasileira Farmacognosia 2014;24:322-9.
6. Sim GS. Structure-activity relationship of antioxidantive property of flavonoids and inhibitory effect on matrix metalloproteinase activity in UVA-irradiated human dermal fibroblast. Arch Pharm Res 2007;30:290-8.
7. Bors W. Flavonoids as antioxidants: determination of radical-scavenging efficiencies, in methods in enzymology, Academic Press; 1990. p. 343-55.
8. Saija A. Flavonoids as antioxidant agents: the importance of their interaction with biomembranes. Free Radical Biol Med 1995;19:491-6.
9. Priyanga KS, VK. Investigation of antioxidant potential of quercetin and hesperidin: an in vitro approach. Asian J Pharm Clin Res 2017;10:83-6.
10. Sivapritya V. Novel nanocarriers for ethnopharmacological formulations. Int J Appl Pharm 2018;10:26-30.
11. Olivella MS. Effects of dimethyl and menthol permeation enhancers: evaluation by skin microdialysis in rats. J Pharm Pharmacol 2007;59:49-54.
12. Tan Q. Preparation and evaluation of quercetin-loaded chitin-chitosan nanoparticles for topical delivery. Int J Nanomed 2014;9:1621-30.
13. Kazi KM. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res 2010;1:374-80.
14. Jain S, A Diwan, S Sardana. Use of lactic acid and span 80 in the formulation of lipid-based imiquimod vesicles for genital warts. Int J Pharm Sci 2017;9:292-301.
15. Gizawy SE. Betamethasone dipropionate gel for the treatment of localized plaque psoriasis. Int J Pharm Sci 2017;9:173-82.
16. Cvee G, A Schatzlein, H Richardsen. Ultraformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double-label CLSM experiments and direct size measurements. Biochim Biophysica Acta 2002;1564:21-30.
17. Elsayed MM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm 2007;332:1-16.
18. Myers RH, DC Montgomery. Response surface methodology: product and process optimization using designed experiments. 2nd Edition ed. John Wiley and Sons, New York; 2002.
19. Rogerson A. The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol 1998;50:337-42.
20. Ichino T. Antitumor effect of liposome-entrapped adriamycin administered via the portal vein. Japan J Cancer Res 1990;81:1052-6.
21. Wang J. Nanoparticle amphiphilic macromolecules as lipoprotein inhibitors: the role of charge and architecture. Int J Nanomed 2007;2:697-705.
22. Jain S. Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluation. AAPS PharmSciTech 2005;6:E513-22.
23. AOAC. Official method of Analysis. 20th Edition. Association of Official Analytical Chemists. Washington DC; Method; 2016. p. 935.14, 992.24.
24. Shen LN. Enhanced in vitro and in vivo skin deposition of apigenin delivered using ethosomes. Int J Pharm 2014;460:280-8.
25. Begas E. Simple and reliable HPLC method for the monitoring of methotrexate in osteosarcoma patients. J Chromatogr Sci 2014;52:590-5.
26. Sendecki GW, WE, Coehorn statistical methods. 7th. Press: Ames Iowa, Iowa State Univ; 1980. p. 507.
27. Primarizky H, Yuniarti WM, Lukiswanto BS. Ellagic acid activity in healing process of the incision wound on male albino rats (Rattus norvegicus). KnE Life Sci 2017;3:224-33.
28. Beutler E, O Duron, BM Kelly. Improved method for the determination of blood glutathione. J Lab Clin Med 1963;61:882-8.
29. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1979;95:351-8.
30. Montgomery HAC, Dymock JF. Colorimetric determination of nitrite. Analyst 1961;86:414.
31. Cornall AG, Cj Bardawill, MM David. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949;177:75-1-66.
32. Koracevic D. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 2001;54:356-61.
33. Bancroft O D, A Stevens. Theory and practice of histological technique. Churchill Livingstone, Edinburgh. London and New York; 2010.
34. Batavia R. The measurement of beclomethasone dipropionate entrapment in liposomes: a comparison of a microscope and an HPLC method. Int J Pharm 2001;212:109-19.
35. Verma DD. Particle size of liposomes influences the dermal delivery of substances into skin. Int J Pharm 2003;258:141-51.
36. Plessis D. The influence of particle size of liposomes on the disposition of drug into the skin. Int J Pharm 1999;199:277-82.
37. Dae S, WK Ng, RB Tan. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterization and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012;47:139-51.
38. Cevc G. Transdermal drug delivery of insulin with ultraformable carriers. Clin Pharmacokinet 2003;42:461-74.
39. Zeisig R, Shimada K, Hirota S, Arndt D. Effect of surfactants on macrophage uptake in vitro and on thickness of the fused aqueous layer of liposomes made from α/β-phospholipid Biochim Biophys Acta 1285;1996:237-45.
40. Muller RH, C Jacobs, O Kayser. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Delivery Rev 2001;47:3-19.
41. Abd-Elal RMA. Trans-nasal zolmitriptan nanosuspensions: in vitro preparation, optimization and in vivo evaluation of brain targeting efficiency. Drug Delivery 2016;23:3374-86.
42. Abu El-Enin ASM. Proniosomal gel-mediated topical delivery of fluconazole: Development, in vitro characterization, and microbiological evaluation. J Adv Pharm Technol Res 2019;10:20-6.
43. Chain E, I Kemp. The isoelectric points of lecithin and sphingomyelin. Biochim J 1934;28:2052-5.
44. Pichot R, RL Watson, IT Norton. Phospholipids at the interface: current trends and challenges. Int J Mol Sci 2013;14:11767-94.
45. Lim WM. Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. Int J Nanomed 2014;9:2117-26.
46. Anwer MK. Development and evaluation of PLGA polymer-based nanoparticles of quercetin. Int J Biomed Macromol 2016;92:213-9.
47. Pannserumlavm Aks AR. Isolation, characterization and formulation properties of new plant gum obtained from mangifera indica. Int J Pharm Biomed Res 2010;3:35.
48. SF Ibrahim ESE, Aa KES. Thermal analysis and characterization of some cellulosic fabrics dyed by a new natural dye and mordanted with different mordants. Int J Chem 2011;3:40.
49. Zafeiri I. The role of surface-active species in the fabrication and functionality of edible solid lipid particles: J Gellod Interface Sci 2017;500:228-40.
50. Avadhani KS. Skin delivery of epigallocatechin-3-gallate (EGCG) and hyaluronic acid loaded nano-transfersomes for antioxidant and anti-aging effects in UV radiation-induced skin damage. Drug Delivery 2017;24:61-74.
51. Sri KV. Preparation and characterization of quercetin and rutin cycloexodrin inclusion complexes. Drug Dev Ind Pharm 2007;33:245-53.
52. Basha MAES A, Shamna R, Awad GJ. Design and optimization of surfactant-based nanovesicles for ocular delivery of clotrimazole. Liposome Res 2013;23:203-10.
53. Nasr AG, Aghrab M. Novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of olmesartan medoxomil: Design, formulation, pharmacokinetic and bioavailability evaluation. Pharmaceutics 2016;8:20.
54. Rajan R. Transfersomes-a vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Techn Res 2011;2:138-43.
55. Rai S, V Pandey, G Rai. Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: the state of the art. Nano Rev Exp 2017;8:1325708.
56. Song HS. The effect of curcumin on wound healing in skin- incised mice. Korean J Physiol Pharmacol 2008;12:343-7.
57. Musalmah M. Comparative effects of palm vitamin E and alpha tocopherol on healing and wound tissue antioxidant enzyme levels in diabetic rats. Lipids 2005;40:575-80.
58. Sinno H. The effects of topical collagen treatment on wound healing and scar cosmesis in rats. Canadian J Plastic Surgery 2012;20:181-5.
59. Weindl G. Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol 2004;17:207-13.
60. Boots AW. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 2008;24:703-10.
61. Schafer M, S Werner. Oxidative stress in normal and impaired wound repair. Pharmacol Res 2008;58:165-71.
62. Huxtable RJ. Physiological actions of taurine. Physiol Rev 1992;72:101-63.
63. Dincer S. Effect of taurine on wound healing. Amino Acids 1996;10:59-71.
64. Henderson WR, M Kaliner. Immunologic and nonimmunologic generation of superoxide from mast cells and basophils. J Clin Investigation 1978;62:187-96.
65. Fu J. Quercetin promotes diabetic wound healing via switching macrophages from M1 to M2 polarization. J Surgical Res 2020;246:213-23.